Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1997-02-03
1999-02-02
Eisenschenk, Frank C.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
53038822, 53038823, 53038825, 435332, 435334, 435337, 4241521, C07K 1600, C07K 1628, C12N 518
Patent
active
058666893
ABSTRACT:
Monoclonal antibodies recognizing gp130 protein and binding to the protein to inhibit IL-6 functions completely (that is to the same level as that is the absence of IL-6) when present in enough amount; a hybridoma producing the monoclonal antibody; a process for production of the monoclonal antibodies using the hybridoma; and an inhibitory agent for inhibition of physiological actions of IL-6 comprising the monoclonal antibodies.
REFERENCES:
Hirano et al. "Biological and clinical aspects of interleukin 6," Immunology Today 11(12):443-449 (1990).
Hirata et al. "Characterization of IL-6 Receptor Expression By Monoclonal And Polyclonal Antibodies," Journal of Immunology 143(9):2900-2906 (Nov. 1, 1989).
Ip et al. "CNTF and LIF Act on Neuronal Cells via Shared Signaling Pathways That Involve the IL-6 Signal Transducing Receptor Component gp130," Cell 69:1121-1132 (Jun. 26, 1992).
Kishimoto et al. "Antibody Against gp130 Protein," Patent Abstracts of Japan 15(500):C-0895 (Dec. 18, 1991).
Klein et al. "Interleukin 6 is the central tumor growth factor in vitro and in vivo in multiple myeloma," Eur. Cytokine Net.1(4):193-201 (Oct.-Nov. 1990).
Liu et al. "Interleukin-6 Signal Transducer gp 130 Mediates Oncostatin M Signalling," The Journal of Biological Chemistry 267(24):16763-16766 (Aug. 25, 1992).
Suzuki et al. "Anti-murine IL-6 receptor antibody inhibits IL-6 effects in vivo," Immunology Letters 30:17-22 (1991).
Suzuki et al. "Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo," Eur. J. Immunol. 22:1989-1993 (1992).
Thorpe, "Monoclonal antibodies: clinical and regulatory issues," TIBTECH 11:40-42 (Feb. 1993).
Yasukawa et al. "Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL-6 and soluble IL-6 receptor, and establishment of an ELISA . . ." Chem. Abstr. 116:149749x (1992).
Search Report for corresponding European application EP-93-30-3276.
Harris et al. "Therapeutic antibodies--the coming of age," TIBTECH 11:42-44 (Feb. 1993).
Hibi et al. "Molecular Cloning and Expression of an IL-6 Signal Transducer, gp130," Cell 63: 1149-1157 (Dec. 21, 1990).
Osband et al. "Problems in the investigational study and clinical use of cancer immunotherapy," Immunology Today 11: 193-195 (1990).
Rein, "Another sepsis drug down--Immunex' TNF receptor," Biotechnology Newswatch, 1,3 (Oct. 4, 1993).
Taga et al. "Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukein 6 signal transducer gp130," Proc. Nat'l Acad. Sci. USA 89:10998-11001 (Nov. 1992).
Winter et al. "Man-made antibodies," Nature 349: 293-299 (Jan. 24, 1991).
Yasukawa et al. "Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of . . .," Immunology Lett. 31: 123-130 (Feb. 1992).
Kishimoto Tadamitsu
Miki Daisuke
Saito Takashi
Suzuki Hiroshi
Yasukawa Kiyoshi
Eisenschenk Frank C.
Kishimoto Tadamitsu
Tosoh Corporation
LandOfFree
Monoclonal antibodies to GP130 protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies to GP130 protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies to GP130 protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1118481